Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19633842 | 0.89 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AHTTTPSAB1 | |
| SCHEMBL24279731 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AHTTTPSAB1 | |
| SCHEMBL18499692 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AHTTTPSAB1 | |
| SCHEMBL15382668 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AHTTTPSAB1 | |
| SCHEMBL23054326 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AHTTTPSAB1 | |
| SCHEMBL23054325 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AHTTTPSAB1 | |
| SCHEMBL12698542 | 0.88 | HTT (0.48) | SMN1; SMN2NPC1RAB9AHTTTPSAB1 | |
| SCHEMBL18494908 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AHTTMEN1 | |
| SCHEMBL20056881 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AHTTTPSAB1 | |
| SCHEMBL24252193 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AHTTTPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558127-B1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | SEAGEN INC (US) | 2022-01-19 | — | — | EP | disclosed |
| WO-2021104834-A1 | COMBINATION THERAPY | ADC THERAPEUTICS SA (CH) | 2021-06-03 | — | — | WO | disclosed |
| WO-2020245283-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC THERAPEUTICS SA (CH) | 2020-12-10 | — | — | WO | disclosed |
| WO-2018107109-A1 | NOVEL ANTI-KREMEN2 ANTIBODIES AND METHODS OF USE | ABBVIE STEMCENTRX LLC (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018107116-A1 | METHODS OF REDUCING TOXICITY OF ANTIBODY DRUG CONJUGATES, AND COMPOSITIONS PRODUCED THEREBY | ABBVIE STEMCENTRX LLC (US) | 2018-06-14 | — | — | WO | disclosed |
| EP-3309162-A1 | TARGETED CONJUGATES OF PYRROLOBENZODIAZEPINES | Seattle Genetics, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| WO-2017193096-A1 | NOVEL ANTI-TNFRSF21 ANTIBODIES AND METHODS OF USE | ABBVIE STEMCENTRX LLC (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017184942-A1 | NOVEL ANTI-BMPR1B ANTIBODIES AND METHODS OF USE | ABBVIE STEMCENTRX LLC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017112811-A1 | NOVEL ANTI-TNFSF9 ANTIBODIES AND METHODS OF USE | ABBVIE STEMCENTRX LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| EP-2558445-B1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES | MEDIMMUNE LTD (GB) | 2017-03-22 | — | — | EP | disclosed |
| WO-2017031458-A2 | ANTI-DLL3 ANTIBODY DRUG CONJUGATES AND METHODS OF USE | ABBVIE STEMCENTRX LLC (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2013055990-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEATTLE GENETICS, INC. (US) | 2013-04-18 | — | — | WO | disclosed |